Pages that link to "Q416451"
Jump to navigation
Jump to search
The following pages link to azacitidine (Q416451):
Displaying 50 items.
- acute myeloid leukemia (Q264118) (← links)
- myelodysplastic syndrome (Q954625) (← links)
- chronic myelomonocytic leukemia (Q1088072) (← links)
- myelofibrosis (Q1752571) (← links)
- A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers (Q26743743) (← links)
- fazarabine (Q27262921) (← links)
- Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature (Q28078522) (← links)
- Vidaza (Q29006647) (← links)
- Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment. (Q34676418) (← links)
- The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA. (Q37702494) (← links)
- Epigenetic therapy in urologic cancers: an update on clinical trials. (Q37707110) (← links)
- Anti-oxidative and anti-inflammatory benefits of the ribonucleoside analogue 5-azacitidine in mice with acetaminophen-induced toxic hepatitis (Q38795905) (← links)
- Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. (Q40360434) (← links)
- The opposed effect of 5-azacytidine and light on the development of reproductive structures in Neurospora crassa (Q43883334) (← links)
- Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. (Q50042689) (← links)
- refractory anemia with excess blasts in transformation (Q55785650) (← links)
- Sorafenib / Azacytidine combination therapy (Q59278117) (← links)
- BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes (Q61807137) (← links)
- An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML) (Q61862174) (← links)
- A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) (Q61862214) (← links)
- An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (Q61862232) (← links)
- A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation (Q61862273) (← links)
- Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes (Q61894311) (← links)
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (Q61894499) (← links)
- Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) (Q61904981) (← links)
- EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (Q61905127) (← links)
- Guadecitabine Extension Study (Q61907444) (← links)
- A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer (Q61908775) (← links)
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma (Q61909218) (← links)
- Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia (Q61915284) (← links)
- Azacytidine and Valproic Acid in Patients With Advanced Cancers (Q61917487) (← links)
- SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome (Q61917558) (← links)
- Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia (Q61917893) (← links)
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (Q61920712) (← links)
- A Phase II Study of Maintenance With Azacitidine in MDS Patients (Q61924449) (← links)
- Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Q61924899) (← links)
- Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) (Q61936355) (← links)
- Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia (Q61936869) (← links)
- Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) (Q61938394) (← links)
- ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) (Q61939162) (← links)
- Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) (Q61939402) (← links)
- Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (Q61957055) (← links)
- Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) (Q61965699) (← links)
- PRO#0118: Decitabine Plus Mini Flu-Bu (Q61966137) (← links)
- In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease (Q61966951) (← links)
- Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies (Q61969478) (← links)
- Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse (Q61969677) (← links)
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (Q61969843) (← links)
- SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) (Q61975685) (← links)
- A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients (Q61980115) (← links)